Key Retreatment Decisions in the Clinical Trials for Faricimab in nAMD


Dr Varun Chaudhary presents the retreatment decisions during the treat-and-extend phase of the TENAYA and LUCERNE clinical trials in neovascular AMD, focusing on the percentage of patients who maintained, extended, or reduced their treatment interval based on visual and anatomic criteria.

Related Videos
Kasperi Kankare at the iCare booth at ESCRS
Megan Baldwin, PhD, CEO and managing director of Opthea Limited, speaking at ASRS 2023.
Nancy Lurker, Executive Vice-Chair of the Board of EyePoint Pharmaceuticals, at ASRS 2023.
Baruch Kupperman, MD, PhD, speaks with David Hutton of Ophthalmology Times.
Related Content
© 2023 MJH Life Sciences

All rights reserved.